- Titre officiel
- A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
- Condition
- Bipolar 1 Disorder
- Statut
- Recrutement en cours
- Phase
- Phase 2
- Sponsor / affiliation principale
- Rapport Therapeutics Inc.
- Intervention
- RAP-219, Placebo
- Pays
- États-Unis
- Contact
- Dawn F Fenton, Leslie Smith, MD, Robert Billingsley, MD, Charmaine Semeniuk, MD, Charmaine Semeniuk, Haig Goenjian, MD, Haig Goenjian, Daniel Chueh, MD, Mohammad Asim Nisar, MD, Patrick Pinchinat, MD, Patrick Pinchinat, Edwin Gomez, MD, Rishi Kakar, MD, Danesh Alam, MD, Kimball Johnson, MD, Roueen Rafeyan, MD, Kulsoom Juniad, MD, Peter Weiden, Peter Weiden, MD, Kurian Abraham, MD, Kurian Abraham, Samuel Collier, MD, Dominick D'Aunno, MD
- Email
- dfenton@rapportrx.com
- Téléphone
- (857) 323-9048
- Registre
- ClinicalTrials.gov